An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04113616 |
|
Recruitment Status :
Recruiting
First Posted : October 3, 2019
Last Update Posted : November 26, 2019
|
Sponsor:
Kartos Therapeutics, Inc.
Information provided by (Responsible Party):
Kartos Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive KRT+232 with LDAC or KRT-232 with Decitabine.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) | Drug: KRT-232 Drug: Cytarabine Drug: Decitabine | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 160 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) |
| Actual Study Start Date : | September 25, 2019 |
| Estimated Primary Completion Date : | December 15, 2023 |
| Estimated Study Completion Date : | July 15, 2024 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Core binding factor acute myeloid leukemia
Cytogenetically normal acute myeloid leukemia
Familial acute myeloid leukemia with mutated CEBPA
| Arm | Intervention/treatment |
|---|---|
|
Experimental: KRT-232+LDAC
KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with LDAC administered at 20 mg/m2/day subcutaneously on Days 1-10 in a 28-day cycle.
|
Drug: KRT-232
KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth. Drug: Cytarabine Cytarabine is an anti-cancer chemotherapy drug taken via injection.
Other Names:
|
|
Experimental: KRT-232(7-Day)+Decitabine
KRT-232 will be administered orally, once daily (QD), on Days 1-7 in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.
|
Drug: KRT-232
KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth. Drug: Decitabine Decitabine is an anti-cancer chemotherapy drug taken via injection.
Other Name: Dacogen |
|
Experimental: KRT-232(14-Day)+Decitabine
KRT-232 will be administered orally, once daily (QD), on Days 1-7 and Days 15-21 (7 days on/7 days off/7 days on/7 days off) in combination with Decitabine administered at 20 mg/m2/day intravenously on Days 1-5 in a 28-day cycle.
|
Drug: KRT-232
KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth. Drug: Decitabine Decitabine is an anti-cancer chemotherapy drug taken via injection.
Other Name: Dacogen |
Primary Outcome Measures :
- Part A: Number of dose-limiting toxicities (DLTs) of KRT-232 in combination with cytarabine or decitabine [ Time Frame: 28 Days ]
- Part B: Proportion of patients achieving complete remission (CR) or complete remission with partial hematological improvement (CRh) as determined by European LeukemiaNet (ELN) response criteria [ Time Frame: 28 Days ]
Secondary Outcome Measures :
- Part A: Proportion of patients achieving complete remission (CR) or complete remission with partial hematological improvement (CRh) as determined by European LeukemiaNet (ELN) response criteria [ Time Frame: 28 Days ]
- Proportion of patients achieving a morphologic leukemia-free state (MLFS), or complete remission with incomplete hematology recovery (CRi), or composite complete remission (CRc = CR + CRh), or partial remission (PR) [ Time Frame: 28 Days ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Part A: Patients with relapsed or refractory AML, or newly-diagnosed AML secondary to MPN
- Part B: Patients with AML secondary to MPN or JAK2 mutation positive AML; patients may have been treated with 0 to 2 prior lines of therapy for their AML
- Adequate hepatic and renal function
- Appropriate prior treatment with an FLT3 or IDH1/2 inhibitor where applicable
Key Exclusion Criteria:
- Patients who are TP53 mutation positive
- Prior treatment with an MDM2 antagonist therapy
- Patients treated with ≥ 18 g/m2 of cytarabine within the prior 90 days are not eligible to be treated with cytarabine on this study (but may be treated with decitabine)
- Patients previously treated with decitabine are not eligible to receive decitabine on this study (but may be treated with cytarabine)
- Patients who have received an allogeneic HSCT within 90 days of enrollment or are eligible for an allogeneic HSCT and have a donor (unless transplant is refused)
- Active graft-versus-host disease requiring active therapy or who have received immunosuppressive therapy for graft-versus-host disease within 1 month prior
- Patients with known CNS involvement with AML, acute promyelocytic leukemia (APL), or a history of bleeding diathesis
- Patients who have had major surgery within 28 days prior
- Women who are pregnant or breastfeeding
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04113616
Contacts
| Contact: Josh Martino | 858-692-4700 | jmartino@kartosthera.com | |
| Contact: John Mei | 650-542-0136 | jmei@kartosthera.com |
Locations
| United States, Ohio | |
| The Ohio State University | Recruiting |
| Columbus, Ohio, United States, 43210 | |
Sponsors and Collaborators
Kartos Therapeutics, Inc.
| Responsible Party: | Kartos Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT04113616 History of Changes |
| Other Study ID Numbers: |
KRT-232-104 |
| First Posted: | October 3, 2019 Key Record Dates |
| Last Update Posted: | November 26, 2019 |
| Last Verified: | November 2019 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Myeloproliferative Disorders Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases Hematologic Diseases Cytarabine Decitabine |
Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Antiviral Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Enzyme Inhibitors |